Caseware UK (AP4) 2023.0.135 2023.0.135 2024-01-312024-01-312023-01-18true1truefalseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 14602226 2023-01-17 14602226 2023-01-18 2024-01-31 14602226 2022-01-18 2023-01-17 14602226 2024-01-31 14602226 c:Director1 2023-01-18 2024-01-31 14602226 d:CurrentFinancialInstruments 2024-01-31 14602226 d:CurrentFinancialInstruments d:WithinOneYear 2024-01-31 14602226 d:ShareCapital 2024-01-31 14602226 d:SharePremium 2024-01-31 14602226 d:RetainedEarningsAccumulatedLosses 2024-01-31 14602226 c:OrdinaryShareClass1 2023-01-18 2024-01-31 14602226 c:OrdinaryShareClass1 2024-01-31 14602226 c:FRS102 2023-01-18 2024-01-31 14602226 c:AuditExempt-NoAccountantsReport 2023-01-18 2024-01-31 14602226 c:FullAccounts 2023-01-18 2024-01-31 14602226 c:PrivateLimitedCompanyLtd 2023-01-18 2024-01-31 14602226 6 2023-01-18 2024-01-31 14602226 e:PoundSterling 2023-01-18 2024-01-31 xbrli:shares iso4217:GBP xbrli:pure
Registered number: 14602226














AMMONITE PHARMACEUTICALS LTD

 
UNAUDITED

DIRECTOR'S REPORT AND FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 JANUARY 2024

 
AMMONITE PHARMACEUTICALS LTD
REGISTERED NUMBER:14602226

BALANCE SHEET
AS AT 31 JANUARY 2024

2024
Note
£

Fixed assets
  

Investments
 4 
1

  
1

Current assets
  

Debtors: amounts falling due within one year
 5 
399,446

  
399,446

Creditors: amounts falling due within one year
 6 
(219,148)

Net current assets
  
 
 
180,298

Total assets less current liabilities
  
180,299

  

Net assets
  
180,299


Capital and reserves
  

Called up share capital 
 7 
1,000

Share premium account
  
184,100

Profit and loss account
  
(4,801)

  
180,299


The director considers that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
D Tanna
Director

Date: 9 September 2024

1

 
AMMONITE PHARMACEUTICALS LTD
REGISTERED NUMBER:14602226
    
BALANCE SHEET (CONTINUED)
AS AT 31 JANUARY 2024

The notes on pages 3 to 4 form part of these financial statements.

2

 
AMMONITE PHARMACEUTICALS LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 JANUARY 2024

1.


General information

The Ammonite Pharmaceuticals Ltd is a private company, limited by shares, registered in England and Wales, registration number 14602226. The registered address of the company is Elsley Court, 20-22 Great Titchfield Street, London, W1W 8BE. 
The principal activity of the company is that of a holding company whose activity is the operation of a pharmacy.
The company was incorporated on 18 January 2023 and commenced trading on 26 January 2023.
 
2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The company's functional and presentational currency is pound sterling.

The following principal accounting policies have been applied:

 
2.2

Exemption from preparing consolidated financial statements

 The company, and the group headed by it, qualify as small as set out in section 383 of the Companies Act 2006 and the parent and group are considered eligible for the exemption to prepare consolidated accounts.

 
2.3

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.4

Debtors

Short term debtors are measured at transaction price, less any impairment.

 
2.5

Creditors

Short term creditors are measured at the transaction price.

 
2.6

Financial instruments

The company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors, creditors and loans with related parties.


3.


Employees




The average monthly number of employees, including the director, during the period was 1.

3

 
AMMONITE PHARMACEUTICALS LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 JANUARY 2024

4.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


Additions
1



At 31 January 2024
1





5.


Debtors

2024
£


Amounts owed by group undertakings
399,446



6.


Creditors: Amounts falling due within one year

2024
£

Other creditors
214,900

Accruals and deferred income
4,248

219,148



7.


Share capital

2024
£
Allotted, called up and fully paid


1,000 Ordinary shares shares of £1.00 each
1,000


100 ordinary shares of £1 were issued on incorporation at a nominal value of £100.
On 27 January 2023, 900 ordinary shares were issued at an aggregate nominal value of £900 for an aggregate subscription price of £185,000.


8.


Related party transactions

No disclosure has been made of transactions with other wholly owned group companies in accordance with FRS 102 Section 1A paragraph 1AC.35.
 
4